Detalhe da pesquisa
1.
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Lancet Oncol
; 25(4): 518-528, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547895
2.
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Br J Cancer
; 130(3): 442-449, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102227
3.
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Gastric Cancer
; 26(3): 425-437, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36881202
4.
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
N Engl J Med
; 379(25): 2395-2406, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30575490
5.
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Gut
; 69(3): 531-539, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101691
6.
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Oncology
; 90(2): 88-96, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26784946
7.
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Support Care Cancer
; 24(5): 1991-1998, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26507190
8.
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
Eur J Cancer
; 202: 114033, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38537314
9.
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
J Clin Oncol
; 42(9): 1067-1076, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963313
10.
Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
Dig Liver Dis
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38762353
11.
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Eur J Cancer
; 200: 113587, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340384
12.
Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.
Cancers (Basel)
; 15(7)2023 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046849
13.
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA Netw Open
; 6(9): e2333533, 2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37721754
14.
Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.
Dig Liver Dis
; 54(3): 391-399, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34384712
15.
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Dig Liver Dis
; 54(10): 1335-1341, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35907691
16.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 8(11): 1571-1578, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36048453
17.
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Pancreas
; 50(6): 803-806, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347737
18.
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Eur J Cancer
; 143: 55-63, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33279854
19.
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Cancers (Basel)
; 13(2)2021 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33430396
20.
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.
Front Oncol
; 10: 1304, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32903594